A new risk grouping for IgD myeloma based on analysis of 165 Japanese patients

Shimamoto, Yoshinori; Anami, Yoichi; Yamaguchi, M.

doi:10.1111/j.1600-0609.1991.tb01569.x

Cited by 43 publications

(33 citation statements)

References 20 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IgD myeloma accounts for approximately 2% of all myeloma subtypes [1,3,4]. It can easily be misdiagnosed as light-chain only disease, because there may be no definitive M-protein band as in other subtypes [5][6][7][8].…”

Section: Discussionmentioning

confidence: 99%

“…They observed that an M-spike was visible in only 60%, k light-chain disease in 60%, Bence-Jones proteinuria in 96%, renal failure in 33%, and hypercalcemia in 22%. Shimamoto et al [4] reviewed 165 patients with IgD myeloma and on multivariate analysis identified two prognostic factors, k light-chain and white blood cell count >7 3 10 9 , which helped stratify patients into three prognostic groups (0, 1, or 2 risk factors) affecting PFS. These large studies highlight the role of k-light chain as an adverse prognostic marker.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The outcome of IgD myeloma after autologous hematopoietic stem cell transplantation is similar to other Ig subtypes

et al. 2010

View full text Add to dashboard Cite

IgD myeloma is a rare subtype of myeloma that is associated with an aggressive course, resistance to chemotherapy, and a poor outcome. We identified 17 patients with IgD myeloma, who received a hematopoietic stem cell transplantation (HCT) at our institution between August 1988 and June 2008. Fifteen of these 17 patients underwent an autologous (auto) HCT. Complete responses (CRs) were seen in 6 of 15 (40%) patients; three converted from partial response to CR, two from minimal response to CR, and one from very good partial response to CR. The overall response rate after auto HCT was 86% (13 of 15). Kaplan-Meiers estimates of 3-year progression-free survival (PFS) and overall survival (OS) were 38% and 64%, respectively. Median PFS and OS were 18 and 45 months, respectively. These results were comparable with patients receiving autologous HCT for other Ig subtypes of myeloma. Am. J. Hematol. 85:502-504, 2010. V

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

The outcome of IgD myeloma after autologous hematopoietic stem cell transplantation is similar to other Ig subtypes

et al. 2010

View full text Add to dashboard Cite

show abstract

“…1 Survival of patients with IgD myeloma is generally accepted to be poorer than that of patients with 'common' myelomas. [2][3][4][5] The situation for non-secretory myeloma is less clear; originally thought to confer an adverse prognosis the majority of authorities now suggest that the prognosis of patients with this form of myeloma is similar [6][7][8] to or possibly better 9,10 than that of patients with common myelomas. It should be noted that these results are based on only small numbers of cases in the series reported.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and outcome of autologous transplantation in rare myelomas

Morris¹,

Drake²,

Apperley³

et al. 2010

Haematologica

View full text Add to dashboard Cite

BackgroundAs rare myelomas, i.e. the IgD, IgE, IgM and non-secretory forms, constitute only a small proportion of any study, relatively little is known about their prognosis in the era of peripheral stem cell transplantation. Design and MethodsWe used the European Group for Blood and Marrow Transplantation Myeloma Database to compare the outcome following autologous transplantation of over 20,000 patients with common myelomas (IgG, IgA and light chain myeloma) with the outcome of patients with rare myelomas: 379 IgD, 13 IgE, 72 IgM and 976 non-secretory cases. ResultsThe study confirms the multiple adverse prognostic factors seen in IgD myeloma. Somewhat surprisingly, patients with IgD and non-secretory myeloma both had higher complete remission rates before and after transplantation than patients with common myelomas. However, while the overall survival of patients with non-secretory myeloma was similar to that of the patients with common myelomas, the survival of patients with IgD myeloma was significantly worse (although better than survival rates reported for non-transplanted patients); this was due to higher transplant-related mortality and relapse/progression rates. The post-transplantation survival of patients with IgE or IgM myeloma appears to be very poor. ConclusionsThis study provides data on the biological features of rare myelomas. The overall survival of patients with IgD, IgE or IgM myeloma is poor following autologous transplantation but substantially better than that reported for patients who were not transplanted. Key words: rare myelomas, autologous transplantation, outcome, efficacy. . Haematologica 2010;95(12):2126-2133. doi:10.3324/haematol.2010 This is an open-access paper. © F e r r a t a S t o r t i F o u n d a t i o n Citation: Morris C, Drake M, Apperley J, Iacobelli S, van Biezen A, Bjorkstrand B, Goldschmidt H, Harousseau J-L, Morgan G, de Witte T, Niederwieser D, and Gahrton G for the Myeloma Subcommittee of the Chronic Leukaemia Working Party of the EBMT. Efficacy and outcome of autologous transplantation in rare myelomas Efficacy and outcome of autologous transplantation in rare myelomas

show abstract

“…By contrast, these numbers in IgG multiple myeloma are 59 and 15%, respectively. Patients are usually younger than those with IgG or IgA myeloma and are more likely to present with nonspecific systemic symptoms, a more rapid progressive clinical course, a higher rate of extramedullary involvement and shorter survival time (30,31). Unfortunately, the majority of clinical laboratories do not include IgD in the initial workup of monoclonal gammopathies (32).…”

Section: Discussionmentioning

confidence: 99%

Acute kidney injury in cancer patients and impedance cardiography‑assisted renal replacement therapy: Experience from the onconephrology unit of a Chinese tertiary hospital

Wang

Zhang²,

et al. 2017

Exp Ther Med

View full text Add to dashboard Cite

Abstract. Acute kidney injury (AKI) in cancer patients may disrupt anticarcinogenic treatment and greatly increase associated mortality rates. The present study reported on the management of cancer patients with AKI and, from the nephrologic viewpoint, on the significance of fine volume control during the continuous renal replacement therapy (CRRT). The records of 117 cancer patients with AKI treated over three years were reviewed and their data were compared with those of 120 healthy controls. AKI was defined according to the Kidney Disease: Improving Global Outcomes criteria with serum creatinine levels determined on initial admission and for the diagnosis of AKI. CRRT with concomitant impedance cardiography (ICG) monitoring was performed in 79 patients. On average, AKI manifested as a 1.68±0.38-fold increase in serum creatinine within 10.2±5.7 days. The causes of AKI were diverse, with the major ones being nephrotoxic agents, hypotension and obstructive nephropathy. Renal biopsy confirmed two cases of thrombotic microangiopathy, due to the use of interfon-α and sunitinib malate, respectively, and a third case of cast nephropathy caused by immunoglobulin D multiple myeloma. The patients were generally marantic and had compromised cardiac function compared with the healthy controls. The CRRT prescription was discriminatingly optimized by the ICG parameters effecting discreet fluid balance, as the thoracic fluid content was significantly correlated with the ultrafiltration rate. By considering the causative mechanisms and applying subtle ICG-assisted volume control, the present study may thus help to improve the safety and efficacy of CRRT in cancer patients with AKI. In addition, it provided information to bring advances in onconephrology, a novel nephrological subspecialty field.

show abstract

A new risk grouping for IgD myeloma based on analysis of 165 Japanese patients

Cited by 43 publications

References 20 publications

The outcome of IgD myeloma after autologous hematopoietic stem cell transplantation is similar to other Ig subtypes

The outcome of IgD myeloma after autologous hematopoietic stem cell transplantation is similar to other Ig subtypes

Efficacy and outcome of autologous transplantation in rare myelomas

Acute kidney injury in cancer patients and impedance cardiography‑assisted renal replacement therapy: Experience from the onconephrology unit of a Chinese tertiary hospital

Contact Info

Product

Resources

About